PD-L1 Biomarker Testing Market Revenue, Insights, Overview, Outlook, Analysis | Valuates Reports

PD-L1 Biomarker Testing Market

The global PD-L1 Biomarker Testing market was valued at US$ 2088 million in 2022 and is anticipated to reach US$ 14870 million by 2029, witnessing a CAGR of 38.7% during the forecast period 2023-2029.

Download Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-6F9402/Global_PD_L1_Biomarker_Testing_Market_Size_Status_and_Forecast_2022

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti-PD-1/PD-L1 therapies.

PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.

The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.

PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.

North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.

By Type
• PD-L1 (22C3)
• PD-L1(28-8)
• PD-L1 (SP142)
• PD-L1 (SP263)
By Application
• Hospital
• Diagnostic Center

Key Players
Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences

View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-6F9402/global-pd-l1-biomarker-testing

Similar Reports:

1. https://reports.valuates.com/market-reports/QYRE-Auto-13G6162/global-metabolic-biomarker-testing

2. https://reports.valuates.com/market-reports/QYRE-Auto-3N6385/global-genomics-biomarkers

3. https://reports.valuates.com/market-reports/QYRE-Auto-33J8028/global-non-alcoholic-steatohepatitis-nash-biomarkers

4. https://reports.valuates.com/market-reports/QYRE-Auto-26T14297/global-biomarker-technology

Phone:
U.S. (TOLL FREE) : +1 (315) 215-3225
India: +91 8040957137

Email Id:
Please reach us at sales@valuates.com

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.